Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$10.20
-0.14 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $356.1M · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.0B
P/E
14.8x
↓EV/EBITDA
6.8x
↓ROE
9.5%
↑Gross Margin
48.8%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.4%
FCF CAGR
-20.1%
FCF margin
9.8%
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.63B · net income $286.3M · FCF $356.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.63B | $3.63B | $3.63B | $3.80B | $4.03B |
| Net Income | $286.3M | $286.3M | $230.8M | $320.4M | $302.5M |
| EBITDA | $543.2M | $543.2M | $436.1M | $565.7M | $543.6M |
| EPS | 0.66 | 0.66 | 0.56 | 0.76 | 0.71 |
| Gross Margin | 48.8% | 48.8% | 46.4% | 46.1% | 43.1% |
| Operating Margin | 10.4% | 10.4% | 8.3% | 11.1% | 10.5% |
| Net Margin | 7.9% | 7.9% | 6.4% | 8.4% | 7.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.05 | 0.06 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $356.1M | $356.1M | $351.4M | $399.1M | $699.0M |
| Returns | |||||
| ROE | 9.5% | 9.5% | 9.4% | 13.4% | 13.6% |
| Valuation | |||||
| P/E | 14.78 | 14.78 | 18.16 | 14.24 | 13.87 |
| EV/EBITDA | 6.84 | 6.84 | 6.66 | 4.74 | 5.67 |
| P/B | 1.45 | 1.45 | 1.70 | 1.91 | 1.89 |
| Growth & Yield | |||||
| Revenue Growth | -0.0% | -0.0% | -4.4% | -5.7% | — |
| EPS Growth | 19.1% | 19.1% | -26.4% | 7.3% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.8%
EPS terminal req.
$0.91
Spread vs growth
8.3%
5Y implied EPS CAGR
10.5%
EPS terminal req.
$1.10
Spread vs growth
8.6%
10Y implied EPS CAGR
10.3%
EPS terminal req.
$1.76
Spread vs growth
8.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.1%
Start / end P/E
19.0x → 15.3x
EPS bridge
0.56 → 0.66
Residual
-3.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.